Close

Cytokinetics (CYTK) Presents Additional Omecamtiv Mecarbil Phase 2 Data; Improvement in LA Structure, Function Noted

November 14, 2016 4:18 PM EST Send to a Friend
Cytokinetics, Inc. (Nasdaq: CYTK) announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login